- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05882253
Billedbehandling af prostatacancer ved tidlig påvisning (IMAGINED-forsøg) (IMAGINED)
Validering, kalibrering og oversættelse af restriktionsspektrumbilleddannelsessignalkort for at forbedre MR-diagnostiske muligheder i prostatakræft
The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
A phase 2 prospective, interventional, non-randomized clinical trial design to investigate whether Restricted Spectrum Maps (RSM) attained from RSI-MRI (On-Q Prostate) improves PI-RADS accuracy compared to PI-RADS alone for the detection of clinically significant prostate cancer. Patients who have agreed to undergo an MRI and subsequent prostate needle biopsy will be approached to participate in the trial.
The aims of the study are as follows:
Goal 1. Validate RSI-MRI imaging biomarker performance using a prospective clinical trial.
Goal 2. Calibrate the RSM values across different MRI scanner manufacturers. Goal 3. Translate RSI using a net clinical benefit model.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Jessica Warbrick, ND
- Telefonnummer: 858-249-1240
- E-mail: jwarbrick@health.ucsd.edu
Undersøgelse Kontakt Backup
- Navn: Michael A Liss, MD, PhD
- Telefonnummer: 858-249-1240
- E-mail: liss@health.ucsd.edu
Studiesteder
-
-
California
-
La Jolla, California, Forenede Stater, 92093
- Rekruttering
- University of California, San Diego
-
Ledende efterforsker:
- Michael Liss, MD
-
Kontakt:
- Michael A Liss, MD, PhD
- Telefonnummer: 858-249-1240
- E-mail: Liss@health.ucsd.edu
-
Kontakt:
- Jessica Warbrick, ND
- Telefonnummer: 858-249-1240
- E-mail: jwarbrick@health.ucsd.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Selected to undergo an MRI-fusion prostate needle biopsy of the prostate.
- Able to provide informed consent
Exclusion Criteria:
- prior diagnosis of prostate cancer (Grade Group >1)
- metastatic prostate cancer
- prior prostate cancer treatment
- contraindication to prostate biopsy (e.g., on anticoagulation that cannot be safely discontinued)
- inability to undergo MRI (e.g., too large to be accommodated in a scanner or with an implant incompatible with MRI).
- Bilateral hip replacement
- Unable to provide informed consent.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: MRI imaging using Siemens MRI
Participants enrolled will undergo routine Magnetic Resonance Imaging (MRI) to obtain Restricted Spectrum Mapping (RSM). These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image. |
An advanced imaging software that supports improved prostate cancer detection and diagnosis
Andre navne:
|
|
Andet: MRI imaging using Phillips MRI
Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image. |
An advanced imaging software that supports improved prostate cancer detection and diagnosis
Andre navne:
|
|
Andet: MRI imaging using General Electric (GE) MRI
Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image. |
An advanced imaging software that supports improved prostate cancer detection and diagnosis
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
RSM mapping value
Tidsramme: Baseline to approximately 9 months
|
Radiologists will report a standard Prostate Imaging, Reporting, and Data System (PI-RADS) and document the RSM values associated with each lesion. Change in value will be reported from baseline to routine biopsy follow-up. |
Baseline to approximately 9 months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Michael A Liss, MD, PhD, University of California, San Diego
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HSC20220897H
- R01CA279667 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
There is no plan to make individual participant data (IPD) available to other researchers
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .